🔬 Latest pharma industry updates 👇

🎗️ Moderna’s personalized mRNA cancer therapy intismeran plus Keytruda, significantly reduced melanoma recurrence and distant metastasis in Phase 3, the 1st pivotal success for an individualized mRNA cancer treatment.

💔 Sanofi will cut 229 jobs at Blueprint Medicines, roughly one-third of its workforce, just 1 year after acquiring the biotech for more than $9B.

❌ AstraZeneca discontinued Phase 3 development of bispecific volrustomig in 1st-line metastatic NSCLC after interim analysis indicated the study was unlikely to meet its survival endpoints.

💪 argenx’s Vyvgart Hytrulo met the Phase 3 ALKIVIA primary endpoint in autoimmune myositis, with particularly strong efficacy in immune-mediated necrotizing myopathy and a consistent safety profile.

🔄 Fulcrum Therapeutics will merge with migraine-focused Slate Medicines in a reverse merger, providing a strategic exit after discontinuing its sickle cell program.

🩸 Amylyx Pharmaceuticals’s avexitide met all Phase 3 endpoints in post-bariatric hypoglycemia supporting an NDA filing planned for late 2026 and launched a $350M equity offering.

🤝 BioMarin Pharmaceutical Inc. will acquire Alesta Therapeutics for $275M, adding an experimental rare bone disease therapy that could address one of the company’s largest potential patient populations.

🏭 Roche’s Genentech will invest about $750M to expand its Oregon manufacturing site for prefilled syringes and autoinjectors, creating roughly 250 jobs.

🤝 LEO Pharma acquired global rights to dersimelagon for up to $435M, gaining a potentially 1st-in-class oral treatment for rare light-sensitive disorders EPP and XLP currently under FDA review.

🏛️ Trump nominated Heidi Overton as FDA commissioner, but her appointment is already drawing criticism over vaccine, abortion and MAHA-related positions.

💉 World Health Organization is deploying 70,000 Ervebo doses in DRC, including 20,000 for a Phase 3 trial testing cross-protection against Bundibugyo Ebola and 50,000 for frontline healthcare workers.

🦟 Singapore’s Wolbachia mosquito program is driving dengue cases toward their lowest annual level in more than 20 years, with around 10 million sterile males released weekly.